Qiagen (NASDAQ:QGEN) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, March 15th.
A number of other equities analysts have also recently commented on QGEN. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Friday, December 1st. Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating in a report on Monday, December 11th. Commerzbank restated a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. DZ Bank restated a “neutral” rating on shares of Qiagen in a report on Tuesday, December 19th. Finally, Cowen restated a “hold” rating and issued a $34.00 price objective on shares of Qiagen in a report on Thursday, December 21st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $35.33.
QGEN stock traded down $0.78 during midday trading on Thursday, reaching $31.23. The company had a trading volume of 456,369 shares, compared to its average volume of 1,085,496. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59. Qiagen has a 1 year low of $27.74 and a 1 year high of $36.34.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.43 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.01. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The business had revenue of $396.86 million during the quarter, compared to analysts’ expectations of $394.48 million. sell-side analysts expect that Qiagen will post 1.34 EPS for the current fiscal year.
Qiagen announced that its board has approved a share buyback plan on Wednesday, January 31st that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its stock is undervalued.
A number of large investors have recently bought and sold shares of the stock. Amalgamated Bank raised its holdings in Qiagen by 6.1% during the 4th quarter. Amalgamated Bank now owns 43,980 shares of the company’s stock valued at $1,360,000 after buying an additional 2,523 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in Qiagen by 50.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock valued at $354,000 after buying an additional 3,860 shares during the last quarter. American International Group Inc. bought a new stake in Qiagen during the 4th quarter valued at $154,000. Two Sigma Investments LP raised its holdings in Qiagen by 0.9% during the 4th quarter. Two Sigma Investments LP now owns 594,920 shares of the company’s stock valued at $18,401,000 after buying an additional 5,107 shares during the last quarter. Finally, OxFORD Asset Management LLP raised its holdings in Qiagen by 6.7% during the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after buying an additional 5,116 shares during the last quarter. Institutional investors own 62.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/bidaskclub-downgrades-qiagen-qgen-to-hold.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.